André Mattar

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Antoinette R. Tan, Seock‐Ah Im, André Mattar et al. · The Lancet Oncology · 2020 · 165 citations

Medicine, Oncology, Pharmacology +16

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Komal Jhaveri, Patrick Neven, M.L. Casalnuovo et al. · New England Journal of Medicine · 2024 · 154 citations

Medicine, Oncology, Pharmacology +16

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

Marcelo Madeira, André Mattar, Ângela Flávia Logullo et al. · BMC Cancer · 2013 · 82 citations · Full text

Medicine, Endocrinology, Oncology +15

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2024 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Christian Marth, Richard G. Moore, Mariusz Bidziński et al. · Journal of Clinical Oncology · 2024 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13